EuroBiotech: More Articles of Note

Newspapers
Oncology Venture, which recently picked up a drug from Novartis, agreed to merge with Medical Prognosis Institute. (NS Newsflash/CC BY 2.0)

> Biogen paid Neurimmune $50 million (€42 million) to cut the royalty rate on potential future sales of Alzheimer’s candidate aducanumab by 5%. The transaction gives Swiss biotech Neurimmune a one-time cash boost today in exchange for less cash in the future if aducanumab bucks the odds and delivers positive data in phase 3. Statement

> C4X Discovery and e-Therapeutics teamed up to research novel ways to treat Parkinson’s disease. The collaboration builds on C4X’s work to identify genes associated with the disease. Release 

> Orchard Therapeutics received a rare pediatric disease designation from the FDA. The status covers the gene therapy specialist’s treatment of metachromatic leukodystrophy. Statement 

Whitepaper

Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

> A-Mansia raised €13 million ($16 million). The first close of the series A round equips the Belgian microbiome startup to research active components isolated from the Akkermansia muciniphila bacterium. Release

> Oncology Venture, which recently picked up a drug from Novartis, agreed to merge with Medical Prognosis Institute. Statement   

> Glialign received seed funding to research a cell therapy for peripheral nerve repair. The UCL Technology Fund contributed to the financing. Release

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.